US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-01 07:50:49 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:U.S. Summit for Democracy fans flame of confrontation to tumultuate world
Next:UN chief calls for reaching consensus on climate actions at COP27
You may also like
- Mideast in Pictures: Long road to recovery awaits quake
- Washington DC is crowned the hardest
- Asian film festival welcomes week of Chinese works
- Chinese books on display at Paris Book Festival 2024
- UN chief applauds formation of transitional council in Haiti
- Improved ecological environment attracts common cranes to Karamay, NW China's Xinjiang
- Palestinian new gov't sworn in
- Tourism booms in three
- Eurozone inflation slows to 8.5 pct in January: Eurostat